DuRvalumab (MEDI4736) with ChEmotherapy as First Line TreAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial (DREAM3R)
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.
Primary Objective To determine Overall survival Secondary Objectives PFS (by mRECIST 1.1 for MPM and iRECIST Objective tumour response [(OTR) by mRECIST 1.1 for MPM and iRECIST)] Adverse events (CTCAE v5.0) Health-related quality of life (HRQL, EORTC QLQ-C30, QLQ-LC29, EQ-5D-5L) Healthcare resource use relative to outcomes (incremental cost-effectiveness)
Chemotherapy (NOS); Immunotherapy
AMP-514 (Durvalumab); Alimta (Pemetrexed); Durvalumab (); MEDI4736 (Durvalumab); Paraplatin (carboplatin); Pemetrexed (); carboplatin (); cisplatin ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.